Biotechnology Business
Goldfarb Branham Law Firm Investigating Claims for Talecris Biotherapeutics Holdings Shareholders
Published in Medicine and Law Weekly, July 2nd, 2010
Goldfarb Branham is investigating Talecris Biotherapeutics Holdings Corp. (NASDAQ: TLCR) for shareholders due to the company's agreement to be acquired by Spanish healthcare company Grifols. The national securities law firm is concerned about both the price and process used to sell Talecris. Stockholders with information or concerns about this buyout are encouraged to contact shareholder lawyer Hamilton Lindley by telephone at 877-583-2855 or by email at hlindley@goldfarbbranham.com.
Although at least one analyst has a target price of $30.00 per share, TLCR shareholders will receive only $26.16 in the proposed partial cash and stock deal. Regrettably, the offer price is...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Mental Health
Data on mental health reported by F. Kigozi and co-researchers - U.S. Department of Justice
Department of Justice Observes June 15 as World Elder Abuse Awareness Day - Finkelstein Thompson LLP
Finkelstein Thompson LLP Announces Investigation of Amedisys, Inc. - Dentistry
Free clinics fill gaps in health safety net, survey finds - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
